Syngene International Limited (NSE:SYNGENE)
India · Delayed Price · Currency is INR | Market Cap | 192.08B -33.6% |
| Revenue (ttm) | 37.39B +2.6% |
| Net Income | 3.17B -36.2% |
| EPS | 7.87 -36.2% |
| Shares Out | 398.10M |
| PE Ratio | 61.31 |
| Forward PE | 47.15 |
| Dividend | 1.25 (0.27%) |
| Ex-Dividend Date | Jun 25, 2026 |
| Volume | 5,130,092 |
| Average Volume | 4,371,460 |
| Open | 455.00 |
| Previous Close | 458.10 |
| Day's Range | 453.40 - 490.70 |
| 52-Week Range | 380.00 - 728.60 |
| Beta | 0.03 |
| RSI | 57.31 |
| Earnings Date | Apr 29, 2026 |
About Syngene International
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, prot... [Read more]
Financial Performance
In fiscal year 2026, Syngene International's revenue was 37.39 billion, an increase of 2.64% compared to the previous year's 36.42 billion. Earnings were 3.17 billion, a decrease of -36.17%.
Financial StatementsNews
Syngene International Ltd (BOM:539268) Q4 2026 Earnings Call Highlights: Strong Revenue Growth ...
Syngene International Ltd (BOM:539268) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Profitability Challenges
Top gainers in morning trade: HFCL at ₹116.03 up 8.34%, syngene international at ₹467.65 up 8.21%, gujarat fluorochemicals at ₹3,602.00 up 7.16%
The Indian stock market is experiencing a turbulent session as the Nifty 50 index slips below the 23,900 mark, currently trading at 23,997.55, down 0.74%. The Sensex also reflects this…
Q4 2026 Syngene International Ltd Earnings Call Transcript
Q4 2026 Syngene International Ltd Earnings Call Transcript
Syngene International Transcript: Q4 25/26
FY 2026 saw 3% revenue growth, with Q4 rebounding 13% sequentially despite Librela headwinds. FY 2027 is expected to be flat as Librela impact fades, with margins in the mid-20s and growth resuming in FY 2028. Investments in AI, new facilities, and expanded partnerships position the business for future growth.
Syngene stock jumps 8% despite profit falling 19% — the market is clearly looking past one
Syngene International delivered a weak set of fourth-quarter numbers for FY26 on Wednesday — profit fell 19%, EBITDA dropped 12% and margins contracted by 450 basis points — and yet…
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today?
Biodexa Pharmaceuticals shares are trading sharply higher Thursday afternoon after the company said it partnered with Syngene International. ... Full story available on Benzinga.com
Biodexa Pharmaceuticals Stock Surges 69% Over Partnership With Syngene International
(RTTNews) - Shares of Biodexa Pharmaceuticals Plc (BDRX) are climbing about 69 percent on Thursday morning trading after it announced a partnership with Syngene International Ltd for the manufacture o...
Syngene International shares fall sharply over 7% today: Details here
Shares of Syngene International Ltd witnessed sharp selling pressure in morning trade today, sliding more than 7% and touching a...
Syngene International Ltd (BOM:539268) Q3 2026 Earnings Call Highlights: Navigating Revenue ...
Syngene International Ltd (BOM:539268) Q3 2026 Earnings Call Highlights: Navigating Revenue Challenges and Strategic Growth Initiatives
Q3 2026 Syngene International Ltd Earnings Call Transcript
Q3 2026 Syngene International Ltd Earnings Call Transcript
Syngene International Transcript: Q3 25/26
Q3 revenue declined 3% year-on-year due to a single large molecule product impact, while underlying research and CDMO businesses showed steady growth. Full-year revenue is now expected to decline 3%-5%, with the product headwind persisting into future quarters.
Syngene International extends strategic collaboration with Bristol Myers Squibb Till 2035
Syngene International has announced a major extension of its long-standing strategic collaboration with Bristol Myers Squibb, strengthening their partnership through...
Syngene International Ltd Webinar on Clinical Trials Market Call Transcript
Syngene International Ltd Webinar on Clinical Trials Market Call Transcript
Syngene International Transcript: Status Update
India's clinical research market is rapidly expanding, driven by patient diversity, regulatory improvements, and cost advantages. Syngene has scaled its clinical research capabilities, offering integrated, end-to-end services and leveraging advanced technologies, with strong profitability and no major capacity constraints. A recent global trial win highlights its growing presence.
Syngene International Ltd (BOM:539268) Q2 2026 Earnings Call Highlights: Navigating Growth ...
Syngene International Ltd (BOM:539268) Q2 2026 Earnings Call Highlights: Navigating Growth Amidst Profitability Challenges
Q2 2026 Syngene International Ltd Earnings Call Transcript
Q2 2026 Syngene International Ltd Earnings Call Transcript
Syngene International Transcript: Q2 25/26
Q2 FY26 revenue grew 2% YoY to INR 911 crore, with research services outpacing CDMO, but EBITDA and PAT declined due to inventory correction and higher costs. The company maintained full-year guidance, expanded clinical trial and manufacturing capabilities, and expects stronger H2 performance.
Goldman Sachs maintains buy on Syngene, bullish on FY26 early-teens growth outlook, sees 15.5% upside on Q1 beat and rising CRO-led margin gains
Goldman Sachs has retained a Buy rating on Syngene International, setting a target price of ₹775, which implies a potential upside of 15.5% from the current market price of ₹670.75. The brokerage high...
Syngene International Transcript: Q1 25/26
Q1 FY26 delivered 11% revenue growth and 21% EBITDA growth, led by research services and operational milestones. Full-year guidance is maintained, with inventory adjustments in biologics expected to impact growth in coming quarters.
Syngene Q1 profit up 59% to Rs 87 crore
Syngene International's profit after tax surged 59% to Rs 87 crore in Q1 2025, driven by revenue growth and a tax benefit. Revenue from operations increased by 11% to Rs 875 crore, with EBITDA rising ...
Syngene International Q1 Results: Revenue grows 11% YoY to Rs 790 crore, Net profit jumps 59% YoY
Syngene International Limited reported strong financial results for the quarter ended June 30, 2025 (Q1 FY26), led by higher revenue and improved margins. For the quarter, the company’s revenue from o...
Syngene International receives EIR from USFDA for Biocon Park facility, inspection concludes with VAI classification
Syngene International Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its GMP manufacturing facilities located at Biocon ...
Syngene International Transcript: Q4 24/25
Q4 and FY 2025 saw resilient revenue growth, margin stability, and strategic U.S. biologics facility acquisition. FY 2026 guidance points to early-teens underlying growth, with reported growth tempered by inventory normalization and margin moderation due to new facility ramp-up.
Why are Syngene shares down 10% despite Q4 net profit jumping 2.8% YoY?
Shares of Syngene International Ltd. tumbled 10% to Rs 674.25 in early trade on April 24, making it one of the top losers on the NSE. The sell-off came despite the company reporting a 2.8% year-on-yea...
Syngene International shares hit lower circuit crashing to 10% today after Q4 results
Shares of Syngene International Ltd. dropped 10% to Rs 674.25 in early trade on April 24 after the company posted lower-than-expected Q4 FY25 financials and offered a conservative revenue growth outlo...